RedHill Biopharma Stock (NASDAQ:RDHL)


OwnershipChart

Previous Close

$8.32

52W Range

$6.42 - $82.00

50D Avg

$9.91

200D Avg

$13.66

Market Cap

$10.58M

Avg Vol (3M)

$325.10K

Beta

3.67

Div Yield

-

RDHL Company Profile


RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IL

Employees

53

IPO Date

Jan 07, 2013

Website

RDHL Performance


Latest Earnings Call Transcripts


Q1 22Jun 23, 22 | 1:25 PM
Q4 21Mar 17, 22 | 3:03 PM
Q3 21Nov 30, 21 | 4:09 PM

Peer Comparison


TickerCompany
EVOKEvoke Pharma, Inc.
TKNOAlpha Teknova, Inc.
AQSTAquestive Therapeutics, Inc.
LFCRLifecore Biomedical, Inc.
ORGOOrganogenesis Holdings Inc.
GHSIGuardion Health Sciences, Inc.
ALIMAlimera Sciences, Inc.
ACRXTalphera, Inc.
PTPIPetros Pharmaceuticals, Inc.
CPIXCumberland Pharmaceuticals Inc.
ADMPAdamis Pharmaceuticals Corporation
CYTHCyclo Therapeutics, Inc.
PRFXPainReform Ltd.
AGRXAgile Therapeutics, Inc.
COLLCollegium Pharmaceutical, Inc.
SXTCChina SXT Pharmaceuticals, Inc.